%0 Journal Article
%T EMERGENCE OF CARBAPENEM RESISTANCE AMONG EXTENDED SPECTRUM BETA-LACTAMASE ISOLATE OF Escherichia coli FROM CLINICAL SPECIMENS IN A TERTIARY HOSPITAL, NIGERIA
%A AKUJOBI C.N.
%A EZEANYA C.C.
%J International Journal of Microbiology Research
%D 2013
%I Bioinfo Publications
%X Extended-spectrum ¦Â-lactamases (ES¦ÂLs) are a rapidly evolving group of ¦Â-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are inhibited by clavulanic acid. In this study, the aim was to determine the susceptibility of ES¦ÂL producing clinical isolates of Escherichia coli across various antimicrobial agents according to the Clinical Laboratory Standard Institute (CLSI) new breakpoints. Sixty five clinical isolates of Escherichia coli were collected from a Tertiary Hospital in Nigeria of which forty six ES¦ÂL-producing isolates emerged. Presence of ES¦ÂL was determined by double- disk synergy test, DNA extraction and amplification of ES¦ÂL genes- blaSHV, blaTEM, blaCTX-M by Polymerase Chain Reaction. Susceptibility of the ES¦ÂL-producing isolates was determined by the CLSI agar diffusion method. Utilizing the CLSI new breakpoints, 76.09%, 73.91%, 73.91% and 63.04% were resistant to Cefotaxime, Ceftazidime, Aztreonam and Cefepime respectively. While, 19.6%, 15.2%, 21.7% and 40% were susceptible to Cefotaxime, Ceftazidime, Aztreonam and Cefepime respectively. Furthermore, though a significant number of ES¦ÂL-producing isolates were susceptible to carbapenem; ES¦ÂL isolates that harboured the blaSHV, blaTEM, blaCTX-M genes showed resistance to carbapenem. Thus, carbapenem-resistant ES¦ÂL-producing isolates emerged from this study. In conclusion, Nigeria is a developing country affected by the spread of bacterial strains harbouring ES¦ÂL and with the emergence of carbapenem resistance; it is certain to create significant therapeutic problems as carbapenem is the drug of choice for serious infections caused by ES¦ÂL-producing Escherichia coli.
%K Extended-spectrum ¦Â-lactamases (ES¦ÂLs)
%K Carbapenem-resistance
%K Clinical specimens
%K Escherichia coli isolates
%U http://www.bioinfopublication.org/viewhtml.php?artid=BIA0001711